Keros Therapeutics (NASDAQ:KROS) Shares Gap Down on Analyst Downgrade

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price gapped down prior to trading on Monday after Oppenheimer lowered their price target on the stock from $102.00 to $63.00. The stock had previously closed at $18.83, but opened at $18.25. Oppenheimer currently has an outperform rating on the stock. Keros Therapeutics shares last traded at $19.56, with a volume of 291,495 shares changing hands.

Several other equities research analysts have also recently weighed in on KROS. Cantor Fitzgerald reissued an “overweight” rating on shares of Keros Therapeutics in a research report on Friday, November 22nd. TD Cowen cut shares of Keros Therapeutics from a “buy” rating to a “hold” rating in a research report on Thursday. Jefferies Financial Group initiated coverage on shares of Keros Therapeutics in a research report on Tuesday, November 5th. They set a “buy” rating for the company. Bank of America decreased their price target on shares of Keros Therapeutics from $81.00 to $76.00 and set a “buy” rating for the company in a research note on Thursday, September 12th. Finally, Scotiabank decreased their price target on shares of Keros Therapeutics from $77.00 to $44.00 and set a “sector outperform” rating for the company in a research note on Friday. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average target price of $81.33.

Institutional Trading of Keros Therapeutics

Several large investors have recently added to or reduced their stakes in KROS. KBC Group NV grew its position in Keros Therapeutics by 52.0% during the third quarter. KBC Group NV now owns 1,263 shares of the company’s stock valued at $73,000 after buying an additional 432 shares during the period. Mirae Asset Global Investments Co. Ltd. lifted its holdings in shares of Keros Therapeutics by 26.0% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,357 shares of the company’s stock worth $77,000 after buying an additional 280 shares in the last quarter. Values First Advisors Inc. purchased a new position in shares of Keros Therapeutics in the third quarter worth $89,000. Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Keros Therapeutics in the second quarter worth $128,000. Finally, LMR Partners LLP purchased a new position in shares of Keros Therapeutics in the third quarter worth $213,000. 71.56% of the stock is currently owned by institutional investors.

Keros Therapeutics Stock Up 1.6 %

The firm’s fifty day moving average price is $59.11 and its 200 day moving average price is $52.69. The stock has a market cap of $775.30 million, a PE ratio of -3.61 and a beta of 1.20.

Keros Therapeutics (NASDAQ:KROS) last released its quarterly earnings results on Wednesday, November 6th. The company reported ($1.41) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.28) by ($0.13). The business had revenue of $0.39 million for the quarter. Keros Therapeutics had a negative net margin of 27,890.94% and a negative return on equity of 41.74%. The firm’s quarterly revenue was up 4750.0% compared to the same quarter last year. During the same quarter last year, the firm posted ($1.33) earnings per share. As a group, analysts anticipate that Keros Therapeutics, Inc. will post -5.26 earnings per share for the current fiscal year.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.